Andere talen Syros Pharmaceuticals, Inc.

Aandelen

SYRS

US87184Q2066

Geschatte realtime Cboe BZX Andere beurzen 20:18:34 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,445 ^USD	-5,83%		-17,63%	-43,00%

09/04	Sectorupdate: Aandelen in de gezondheidszorg gemengd in de late middaghandel	MT
09/04	Syros krijgt fast track label voor tamibarotene voor de behandeling van acute myeloïde leukemie; aandelen stijgen	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09/04
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09/04
Syros Gets FDA Fast-Track Designation for Tamibarotene	09/04
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	28/03
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	27/03
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	27/03
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27/03
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	25/03
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	25/03
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	25/03
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	20/03
Syros to Participate in TD Cowen 44th Annual Health Care Conference	27/02
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?	01/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Syros Pharmaceuticals, Inc.

Aandelen

SYRS

US87184Q2066

Andere talen

Filters